AOP-Wiki

API

All Key Events

Showing 1926 to 1946 of 1946 Key Events

ID	Title	Event Component Count	Biological Organization	Created At	Last Updated	AOPs

1075	prolonged, estrus cycle Short Name prolonged, estrus cycle	2	Individual	Nov 29, 2016	Aug 25, 2026	4 AOPs 168: GnRH pulse disruption leading to mammary adenomas and carcinomas in the SD rat. 169: GnRH pulse disruption leading to pituitary adenomas and carcinomas in the SD rat. 609: Activation, estrogen receptor alpha leads to prolonged estrus cycle via decreased kisspeptin release 640: Activation, estrogen receptor alpha leads to decreased fertility via prolonged estrus cycle
2306	Persistent vaginal cornification Short Name Persistent vaginal cornification	1	Tissue	Jan 13, 2025	Aug 25, 2026	2 AOPs 566: Decreased, GnRH pulsatility/release leading to estradiol availability, increased via impaired ovulation 623: Activation, estrogen receptor alpha leads to persistent vaginal cornification via increased kisspeptin release
2365	Anogenital distance (AGD), increased Short Name Anogenital distance (AGD), increased	1	Tissue	Sep 5, 2025	Aug 30, 2026	547: Androgen receptor agonism leading to long anogenital distance (AGD) in female offspring
2448	Brain insulin-degrading enzyme (IDE), inhibition Short Name IDE inhibition	0	Molecular	Aug 31, 2026	Aug 31, 2026	652: Inhibition of brain insulin-degrading enzyme (IDE) leads to cognitive decline (adult)
2449	Brain amyloid-beta (Aβ) accumulation, increased Short Name Abeta accumulation	0	Cellular	Aug 31, 2026	Aug 31, 2026	652: Inhibition of brain insulin-degrading enzyme (IDE) leads to cognitive decline (adult)
2450	Cognitive Decline (Adult) Short Name Cognitive Decline (Adult)	0	Individual	Aug 31, 2026	Aug 31, 2026	652: Inhibition of brain insulin-degrading enzyme (IDE) leads to cognitive decline (adult)
2323	Over-expression of PD-L1 in cancer cells Short Name	1	Molecular	May 15, 2025	Sep 1, 2026	578: AhR activation leading to cancer progression via immunosuppression
1521	Decrease, Growth Short Name Decrease, Growth	1	Individual	May 24, 2018	Sep 2, 2026	27 AOPs 263: Uncoupling of oxidative phosphorylation leading to growth inhibition via decreased cell proliferation 290: Mitochondrial ATP synthase antagonism leading to growth inhibition (1) 291: Mitochondrial ATP synthase antagonism leading to growth inhibition (2) 286: Mitochondrial complex III antagonism leading to growth inhibition (1) 287: Mitochondrial complex III antagonism leading to growth inhibition (2) 245: Reduction in photophosphorylation leading to growth inhibition in aquatic plants 265: Uncoupling of oxidative phosphorylation leading to growth inhibition via increased cytosolic calcium 264: Uncoupling of oxidative phosphorylation leading to growth inhibition via ATP depletion associated cell death 266: Uncoupling of oxidative phosphorylation leading to growth inhibition via decreased Na-K ATPase activity 267: Uncoupling of oxidative phosphorylation leading to growth inhibition via glucose depletion 268: Uncoupling of oxidative phosphorylation leading to growth inhibition via mitochondrial swelling 473: Energy deposition from internalized Ra-226 decay lower oxygen binding capacity of hemocyanin 331: Increase in reactive oxygen species leading to growth inhibition via lipid peroxidation and cell death 596: Excessive reactive oxygen species leading to growth inhibition via protein oxidation and cell injury/death 598: Excessive reactive oxygen species leading to growth inhibition via protein oxidation and reduced cell proliferation 599: Excessive reactive oxygen species leading to growth inhibition via fatty acid oxidation and cell injury/death 600: Excessive reactive oxygen species leading to growth inhibition via fatty acid oxidation and reduced cell growth 602: Excessive reactive oxygen species leading to growth inhibition via oxidative DNA damage 603: Excessive reactive oxygen species leading to growth inhibition via protein oxidation and cell cycle disruption 601: Excessive reactive oxygen species leading to growth inhibition via fatty acid oxidation and reduced cell proliferation 567: Binding to plastoquinone B site leading to decreased population growth rate via photosystem II inhibition 324: Increase in reactive oxygen species leading to growth inhibition via oxidative DNA damage and cell cycle disruption 325: Increase in reactive oxygen species leading to growth inhibition via oxidative DNA damage and cell death 326: Increase in reactive oxygen species leading to growth inhibition via lipid peroxidation and decreased cell proliferation 332: Increase in reactive oxygen species leading to growth inhibition via protein oxidation and decreased cell proliferation 333: Increase in reactive oxygen species leading to growth inhibition via protein oxidation and cell death 647: ROS formation leading to growth inhibition modulated by the Keap1–Nrf2 antioxidant response
1392	Increase, Oxidative Stress Short Name Increase, Oxidative Stress	1	Molecular	May 30, 2017	Sep 2, 2026	71 AOPs 220: Cyp2E1 Activation Leading to Liver Cancer 17: Binding of electrophilic chemicals to SH(thiol)-group of proteins and /or to seleno-proteins involved in protection against oxidative stress during brain development leads to impairment of learning and memory 284: Binding of electrophilic chemicals to SH(thiol)-group of proteins and /or to seleno-proteins involved in protection against oxidative stress leads to chronic kidney disease 377: Dysregulated prolonged Toll Like Receptor 9 (TLR9) activation leading to Multi Organ Failure involving Acute Respiratory Distress Syndrome (ARDS) 411: Oxidative stress Leading to Decreased Lung Function 424: Oxidative stress Leading to Decreased Lung Function via CFTR dysfunction 425: Oxidative Stress Leading to Decreased Lung Function via Decreased FOXJ1 429: A cholesterol/glucose dysmetabolism initiated Tau-driven AOP toward memory loss (AO) in sporadic Alzheimer's Disease with plausible MIE's plug-ins for environmental neurotoxicants 452: Adverse outcome pathway of PM-induced respiratory toxicity 464: Calcium overload in dopaminergic neurons of the substantia nigra leading to parkinsonian motor deficits 470: Deposition of energy leads to abnormal vascular remodeling 478: Deposition of energy leading to occurrence of cataracts 479: Mitochondrial complexes inhibition leading to left ventricular function decrease via increased myocardial oxidative stress 481: AOPs of amorphous silica nanoparticles: ROS-mediated oxidative stress increased respiratory dysfunction and diseases. 482: Deposition of energy leading to occurrence of bone loss 483: Deposition of Energy Leading to Learning and Memory Impairment 505: Reactive Oxygen Species (ROS) formation leads to cancer via inflammation pathway 521: Essential element imbalance leads to reproductive failure via oxidative stress 26: Calcium-mediated neuronal ROS production and energy imbalance 488: Increased reactive oxygen species production leading to decreased cognitive function 396: Deposition of ionizing energy leads to population decline via impaired meiosis 437: Inhibition of mitochondrial electron transport chain (ETC) complexes leading to kidney toxicity 535: Binding and activation of GPER leading to learning and memory impairments 171: Chronic cytotoxicity of the serous membrane leading to pleural/peritoneal mesotheliomas in the rat. 138: Organic anion transporter (OAT1) inhibition leading to renal failure and mortality 177: Cyclooxygenase 1 (COX1) inhibition leading to renal failure and mortality 186: unknown MIE leading to renal failure and mortality 200: Estrogen receptor activation leading to breast cancer 444: Ionizing radiation leads to reduced reproduction in Eisenia fetida via reduced spermatogenesis and cocoon hatchability 447: Kidney failure induced by inhibition of mitochondrial electron transfer chain through apoptosis, inflammation and oxidative stress pathways 476: Adverse Outcome Pathways diagram related to PBDEs associated male reproductive toxicity 497: ERa inactivation alters mitochondrial functions and insulin signalling in skeletal muscle and leads to insulin resistance and metabolic syndrome 457: Succinate dehydrogenase inhibition leading to increased insulin resistance through reduction in circulating thyroxine 459: AhR activation in the thyroid leading to Subsequent Adverse Neurodevelopmental Outcomes in Mammals 507: Nrf2 inhibition leading to vascular disrupting effects via inflammation pathway 509: Nrf2 inhibition leading to vascular disrupting effects through activating apoptosis signal pathway and mitochondrial dysfunction 510: Demethylation of PPAR promotor leading to vascular disrupting effects 511: The AOP framework on ROS-mediated oxidative stress induced vascular disrupting effects 538: Adverse outcome pathway of PFAS-induced vascular disrupting effects via activating oxidative stress related pathways 260: CYP2E1 activation and formation of protein adducts leading to neurodegeneration 450: Inhibition of AChE and activation of CYP2E1 leading to sensory axonal peripheral neuropathy and mortality 501: Excessive iron accumulation leading to neurological disorders 540: Oxidative Stress in the Fish Ovary Leads to Reproductive Impairment via Reduced Vitellogenin Production 471: Neuron defect induced early behavioral change 31: Oxidation of iron in hemoglobin leading to hematotoxicity 534: Succinate dehydrogenase (SDH) inhibition leads to oxidative stress 462: Activation of reactive oxygen species leading the atherosclerosis 331: Increase in reactive oxygen species leading to growth inhibition via lipid peroxidation and cell death 595: Emerging OPFRS reproductive outcome pathway 596: Excessive reactive oxygen species leading to growth inhibition via protein oxidation and cell injury/death 598: Excessive reactive oxygen species leading to growth inhibition via protein oxidation and reduced cell proliferation 599: Excessive reactive oxygen species leading to growth inhibition via fatty acid oxidation and cell injury/death 600: Excessive reactive oxygen species leading to growth inhibition via fatty acid oxidation and reduced cell growth 601: Excessive reactive oxygen species leading to growth inhibition via fatty acid oxidation and reduced cell proliferation 602: Excessive reactive oxygen species leading to growth inhibition via oxidative DNA damage 603: Excessive reactive oxygen species leading to growth inhibition via protein oxidation and cell cycle disruption 608: Thyroid Hormone Excess Leading to Reduced, Swimming Performance via Hypomyelination 616: organic UV filter and its Photoproducts reproductive toxicity pathways 622: Calcineurin inhibitor induced nephrotoxicity leading to kidney failure 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 628: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated oxidative stress 472: DNA adduct formation leading to kidney failure 642: Intestinal FXR inhibition leading to steatohepatitis via gut‑liver axis dysregulation 324: Increase in reactive oxygen species leading to growth inhibition via oxidative DNA damage and cell cycle disruption 325: Increase in reactive oxygen species leading to growth inhibition via oxidative DNA damage and cell death 326: Increase in reactive oxygen species leading to growth inhibition via lipid peroxidation and decreased cell proliferation 332: Increase in reactive oxygen species leading to growth inhibition via protein oxidation and decreased cell proliferation 333: Increase in reactive oxygen species leading to growth inhibition via protein oxidation and cell death 645: Binding and activation of AhR lead to cardiovascular aging 646: Binding and activation of AhR/PPARγ lead to lipid metabolism disorders 647: ROS formation leading to growth inhibition modulated by the Keap1–Nrf2 antioxidant response
1634	Increase, Oxidative DNA damage Short Name Increase, Oxidative DNA damage	1	Molecular	May 19, 2019	Sep 2, 2026	8 AOPs 296: Oxidative DNA damage leading to chromosomal aberrations and mutations 299: Deposition of energy leading to population decline via DNA oxidation and follicular atresia 311: Deposition of energy leading to population decline via DNA oxidation and oocyte apoptosis 478: Deposition of energy leading to occurrence of cataracts 330: Excessive reactive oxygen species production leading to mortality (4) 602: Excessive reactive oxygen species leading to growth inhibition via oxidative DNA damage 324: Increase in reactive oxygen species leading to growth inhibition via oxidative DNA damage and cell cycle disruption 325: Increase in reactive oxygen species leading to growth inhibition via oxidative DNA damage and cell death
1635	Increase, DNA strand breaks Short Name Increase, DNA strand breaks	1	Molecular	May 19, 2019	Sep 2, 2026	13 AOPs 296: Oxidative DNA damage leading to chromosomal aberrations and mutations 272: Deposition of energy leading to lung cancer 322: Alkylation of DNA leading to decreased sperm count 216: Deposition of energy leading to population decline via DNA strand breaks and follicular atresia 238: Deposition of energy leading to population decline via DNA strand breaks and oocyte apoptosis 478: Deposition of energy leading to occurrence of cataracts 483: Deposition of Energy Leading to Learning and Memory Impairment 470: Deposition of energy leads to abnormal vascular remodeling 592: DBDPE-induced DNA strand breaks and LDH activity inhibition leading to population growth rate decline via energy metabolism disrupt and apoptosis 602: Excessive reactive oxygen species leading to growth inhibition via oxidative DNA damage 324: Increase in reactive oxygen species leading to growth inhibition via oxidative DNA damage and cell cycle disruption 325: Increase in reactive oxygen species leading to growth inhibition via oxidative DNA damage and cell death 644: Bulky DNA adducts leading to chromosomal aberrations and mutations
155	Inadequate DNA repair Short Name Inadequate DNA repair	1	Cellular	Nov 29, 2016	Sep 2, 2026	14 AOPs 15: Alkylation of DNA in male pre-meiotic germ cells leading to heritable mutations 141: Alkylation of DNA leading to cancer 2 139: Alkylation of DNA leading to cancer 1 296: Oxidative DNA damage leading to chromosomal aberrations and mutations 272: Deposition of energy leading to lung cancer 322: Alkylation of DNA leading to decreased sperm count 397: Bulky DNA adducts leading to mutations 432: Deposition of Energy by Ionizing Radiation leading to Acute Myeloid Leukemia 443: DNA damage and mutations leading to Metastatic Breast Cancer 478: Deposition of energy leading to occurrence of cataracts 602: Excessive reactive oxygen species leading to growth inhibition via oxidative DNA damage 324: Increase in reactive oxygen species leading to growth inhibition via oxidative DNA damage and cell cycle disruption 325: Increase in reactive oxygen species leading to growth inhibition via oxidative DNA damage and cell death 644: Bulky DNA adducts leading to chromosomal aberrations and mutations
1505	Increase, Cell cycle disruption Short Name Cell cycle disruption	1	Cellular	Jan 21, 2018	Sep 2, 2026	8 AOPs 212: Histone deacetylase inhibition leading to testicular atrophy 393: AOP for thyroid disorder caused by triphenyl phosphate via TRβ activation 396: Deposition of ionizing energy leads to population decline via impaired meiosis 591: DBDPE-induced DNA damage increase in liver leading to Non-alcoholic fatty liver disease via liver steatosis and inhibition of regeneration 602: Excessive reactive oxygen species leading to growth inhibition via oxidative DNA damage 603: Excessive reactive oxygen species leading to growth inhibition via protein oxidation and cell cycle disruption 610: Decreased thyroid hormone levels in the brain regulated via transport, metabolism and TR activation leading to decreased cognition and motor function 324: Increase in reactive oxygen species leading to growth inhibition via oxidative DNA damage and cell cycle disruption
55	Increase, Cell injury/death Short Name Cell injury/death	1	Cellular	Nov 29, 2016	Sep 2, 2026	30 AOPs 48: Binding of agonists to ionotropic glutamate receptors in adult brain causes excitotoxicity that mediates neuronal cell death, contributing to learning and memory impairment. 13: Chronic binding of antagonist to N-methyl-D-aspartate receptors (NMDARs) during brain development induces impairment of learning and memory abilities 38: Protein Alkylation leading to Liver Fibrosis 12: Chronic binding of antagonist to N-methyl-D-aspartate receptors (NMDARs) during brain development leads to neurodegeneration with impairment in learning and memory in aging 144: Endocytic lysosomal uptake leading to liver fibrosis 17: Binding of electrophilic chemicals to SH(thiol)-group of proteins and /or to seleno-proteins involved in protection against oxidative stress during brain development leads to impairment of learning and memory 278: IKK complex inhibition leading to liver injury 281: Acetylcholinesterase Inhibition Leading to Neurodegeneration 273: Mitochondrial complex inhibition leading to liver injury 377: Dysregulated prolonged Toll Like Receptor 9 (TLR9) activation leading to Multi Organ Failure involving Acute Respiratory Distress Syndrome (ARDS) 265: Uncoupling of oxidative phosphorylation leading to growth inhibition via increased cytosolic calcium 264: Uncoupling of oxidative phosphorylation leading to growth inhibition via ATP depletion associated cell death 266: Uncoupling of oxidative phosphorylation leading to growth inhibition via decreased Na-K ATPase activity 268: Uncoupling of oxidative phosphorylation leading to growth inhibition via mitochondrial swelling 479: Mitochondrial complexes inhibition leading to left ventricular function decrease via increased myocardial oxidative stress 490: Co-activation of IP3R and RyR leads to reduced IQ and increased socio-economic burden through non-cholinergic mechanisms 494: AhR activation leading to liver fibrosis 530: Endocytotic lysosomal uptake leads to intestinal barrier disruption 331: Increase in reactive oxygen species leading to growth inhibition via lipid peroxidation and cell death 596: Excessive reactive oxygen species leading to growth inhibition via protein oxidation and cell injury/death 599: Excessive reactive oxygen species leading to growth inhibition via fatty acid oxidation and cell injury/death 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress 627: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated mitochondrial dysfunction 628: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated oxidative stress 629: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated endoplasmic reticulum stress 325: Increase in reactive oxygen species leading to growth inhibition via oxidative DNA damage and cell death 333: Increase in reactive oxygen species leading to growth inhibition via protein oxidation and cell death 647: ROS formation leading to growth inhibition modulated by the Keap1–Nrf2 antioxidant response
1821	Decrease, Cell proliferation Short Name Decrease, Cell proliferation	1	Cellular	Nov 12, 2020	Sep 2, 2026	16 AOPs 263: Uncoupling of oxidative phosphorylation leading to growth inhibition via decreased cell proliferation 290: Mitochondrial ATP synthase antagonism leading to growth inhibition (1) 286: Mitochondrial complex III antagonism leading to growth inhibition (1) 399: Inhibition of Fyna leading to increased mortality via decreased eye size (Microphthalmos) 460: Antagonism of Smoothened receptor leading to orofacial clefting 267: Uncoupling of oxidative phosphorylation leading to growth inhibition via glucose depletion 491: Decrease, GLI1/2 target gene expression leads to orofacial clefting 502: Decrease, cholesterol synthesis leads to orofacial clefting 591: DBDPE-induced DNA damage increase in liver leading to Non-alcoholic fatty liver disease via liver steatosis and inhibition of regeneration 598: Excessive reactive oxygen species leading to growth inhibition via protein oxidation and reduced cell proliferation 602: Excessive reactive oxygen species leading to growth inhibition via oxidative DNA damage 603: Excessive reactive oxygen species leading to growth inhibition via protein oxidation and cell cycle disruption 601: Excessive reactive oxygen species leading to growth inhibition via fatty acid oxidation and reduced cell proliferation 324: Increase in reactive oxygen species leading to growth inhibition via oxidative DNA damage and cell cycle disruption 326: Increase in reactive oxygen species leading to growth inhibition via lipid peroxidation and decreased cell proliferation 332: Increase in reactive oxygen species leading to growth inhibition via protein oxidation and decreased cell proliferation
2451	Increase, TDP-43 aggregation Short Name TDP-43 aggregation	0	Cellular	Sep 6, 2026	Sep 6, 2026	636: Increase in reactive oxygen species (ROS) leading to human amyotrophic lateral sclerosis (ALS)
1329	Brain-derived neurotrophic factor (BDNF) gene expression, reduced Short Name BDNF gene expression, reduced	1	Molecular	Apr 13, 2017	Sep 7, 2026	5 AOPs 214: Network of SSRIs (selective serotonin reuptake inhibitors) 221: Mental stress to depression 222: Mental stress to agitation 225: Serotonin transporter activation to agitation 224: Serotonin transporter activation to depression
2324	Increased of Treg/Th17 cell ratio Short Name Dysregulation of Treg/Th17 cell ratio	0	Cellular	May 16, 2025	Sep 9, 2026	578: AhR activation leading to cancer progression via immunosuppression
2452	Inhibition to Microsomal Triglyceride Transfer Protein Short Name inhbition to MTP	0	Molecular	Sep 9, 2026	Sep 9, 2026	653: Inhibition to Microsomal Triglyceride Transfer Protein Leads to Steatosis
2453	reduced efflux of lipid Short Name reduced lipid efflux	0	Cellular	Sep 9, 2026	Sep 9, 2026	653: Inhibition to Microsomal Triglyceride Transfer Protein Leads to Steatosis
2454	Increase, small intestine steatosis Short Name small intestine steatosis	0	Organ	Sep 9, 2026	Sep 9, 2026	653: Inhibition to Microsomal Triglyceride Transfer Protein Leads to Steatosis